LB PHARMACEUTICALS INC(LBRX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

LB PHARMACEUTICALS INC (LBRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. LBRX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), LB PHARMACEUTICALS INC reports net income of $-51.6M, free cash flow of $-38.0M. Top institutional holders of LBRX by reported 13-F value include Deep Track Capital, BlackRock, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. LBRX trades on the Nasdaq exchange and files with the SEC under CIK 1691082. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LB PHARMACEUTICALS INC directly from SEC EDGAR.

Net Income

$-51.6M

Free Cash Flow

$-38.0M

Institutions holding LBRX

Institutional investors reporting a position in LB PHARMACEUTICALS INC on SEC Form 13F.
InstitutionSharesValueReported
Deep Track Capital3,352,804$108.8M2026-06-30
BlackRock2,734,305$88.7M2026-06-30
RA CAPITAL MANAGEMENT, L.P.2,208,604$71.7M2026-06-30
Trails Edge Capital Partners1,523,022$49.4M2026-06-30
JPMORGAN CHASE1,497,293$48.9M2026-06-30
Commodore Capital1,500,000$48.7M2026-06-30
TCG Crossover Management1,447,310$47.0M2026-06-30
Caligan Partners1,438,070$46.7M2026-06-30
Spruce Street Capital1,376,159$44.7M2026-06-30
Nantahala Capital Management1,052,894$34.2M2026-06-30
LBRX

LB PHARMACEUTICALS INC

LBRX
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q2 2026
EDGAR

$-51.60M

EPS (Diluted)

Q2 2026
EDGAR

$-1.71

ROIC

Q2 2026
EDGAR

-62.1%

Free Cash Flow

Q2 2026
EDGAR

$-37.99M

Top Institutional Holders

as of Q2 2026
$965.86M total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…